Effective resolution of daratumumab‐induced false‐positive antibody screening with commercial reagents

Key Points

• The aim is to evaluate the efficacy of DaraEx in resolving false-positive antibody screenings induced by daratumumab.
• Comparison of DaraEx and DTT in antibody screening
• Assessment of interference in antibody tests
• Evaluation of safety and efficiency of commercial reagents
• DaraEx completely removed DARA-related interference
• DaraEx was effective even when DTT failed
• DaraEx is a safe alternative for pre-transfusion antibody screening

Abstract